Neuropathic pain. NFX88 (based on hydroxioleic acid) is a non-steroideal antiinflammatory drug with GPCR-G protein uncoupling activity that alleviates pain of neural origin. It is formulated for convenient oral administration. NFX88 reduces hyperalgesia, which is a common condition in neurological disorders and neurodegenerative diseases, with higher efficacy than the current reference drug, pregabalin7.

In the long term, the products developed by NEUROFIX have a wide range of applications. Although NFX88 is developed as an orphan drug for the treatment of neuropathic pain in SCI patients, its use can be extended to other type of patients withneuropathic pain, which has a huge market. Within the scope of this proposal, NFX81 and NFX88 provide a new therapeutic approach to neurological diseases based on the rational design of active principles targeted to critical CNS lipids.